Posted by Michael Wonder on 09 Jan 2025
Johnson & Johnson’s posdinemab and tau active immunotherapy receive US FDA fast track designations for the treatment of Alzheimer’s disease
8 January 2025 - Building on decades of the Company’s Alzheimer’s research, two differentiated investigational therapies aim to slow pathological tau in distinct populations.
Johnson & Johnson announced today that the US FDA has granted fast track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated to treat patients with early Alzheimer’s disease in the Phase 2b “AuTonomy” study.
